G.l. Pharma Uk Limited

Gl Pharma Uk Ltd, based in Ely, UK, is a small, active company founded six years ago. Employing just six people, it holds £6,012,079 in assets and operates from a real address. With two directors and one owner, the company regularly imports pharmaceutical products—a total of seven months of import activity recorded, with the last operation occurring in March 2025.

The company’s website paints a picture of a pharmaceutical partner, committed to developing and commercializing innovative medicines. It targets a UK audience and offers a range of services, including product information, career opportunities, and downloadable resources. The site highlights its expertise in substitution therapy and its commitment to research and development, with a focus on partnerships and licensing opportunities. It’s clear they’re aiming for a professional image, showcasing a portfolio of products and a network of specialist groups.

Financially, Gl Pharma Uk Ltd’s recent report reveals some interesting trends. While cash reserves increased by a substantial 2900%, reaching £3.4 million, other areas show signs of change. Creditors have risen significantly, up 320%, and net assets have jumped 450% to £560,000. Interestingly, the average number of employees has decreased by 33%, falling to four. Bank borrowings have also surged by 1000%, reaching £290,000. The company’s small size—meeting two of three criteria for a small company—helps it remain flexible, but the increase in borrowing and decrease in employees could signal a shift in operational strategy. The report, unaudited, relies on director-reported data.

It seems Gl Pharma Uk Ltd is navigating a period of change, potentially investing in growth while managing increased debt. The focus on pharmaceutical products and partnerships suggests a strategic approach, but the financial data warrants careful monitoring.

Registered in England/Wales under the registration number 11829209, with a registered address at CB7 4EX, England, Ely, Suite 3a, 30 St Thomas Place.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.